ENDEAVOR BIOMEDICINES
Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis. The company was founded in 2018 and is based in Solana Beach, California, United States.
ENDEAVOR BIOMEDICINES
Industry:
Biotechnology Health Care Medical
Founded:
2018-01-01
Address:
Solana Beach, California, United States
Country:
United States
Website Url:
http://www.endeavorbiomedicines.com
Total Employee:
11+
Status:
Active
Contact:
858.537.1700
Total Funding:
163 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Wordpress Plugins Global Site Tag
Current Advisors List
Board_member
2021-01-01
Board_member
2020-12-01
Board_member
2022-02-01
Board_member
2022-02-01
Board_member
Current Employees Featured
John Hood Founder and Executive Chairman @ Endeavor BioMedicines
Founder and Executive Chairman
2018-10-01
Miguel de los Rios Co-Founder and Chief Scientific Officer @ Endeavor BioMedicines
Co-Founder and Chief Scientific Officer
2020-09-01
Founder
Investors List
Ally Bridge Group
Ally Bridge Group investment in Series B - Endeavor BioMedicines
T. Rowe Price
T. Rowe Price investment in Series B - Endeavor BioMedicines
Omega Funds
Omega Funds investment in Series B - Endeavor BioMedicines
Perceptive Advisors
Perceptive Advisors investment in Series B - Endeavor BioMedicines
Piper Heartland Healthcare Capital
Piper Heartland Healthcare Capital investment in Series B - Endeavor BioMedicines
Longitude Capital
Longitude Capital investment in Series B - Endeavor BioMedicines
Avidity Partners
Avidity Partners investment in Series B - Endeavor BioMedicines
Revelation Partners
Revelation Partners investment in Series B - Endeavor BioMedicines
Tekla Capital Management
Tekla Capital Management investment in Series B - Endeavor BioMedicines
Omega Funds
Omega Funds investment in Series A - Endeavor BioMedicines
Official Site Inspections
http://www.endeavorbiomedicines.com Semrush global rank: 2.32 M Semrush visits lastest month: 8.03 K
- Host name: ec2-34-206-78-211.compute-1.amazonaws.com
- IP address: 34.206.78.211
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Endeavor BioMedicines"
About Us - Endeavor BioMedicines
A Culture of Going Beyond We believe in pushing the boundaries of medical innovation to create new therapeutic possibilities for patients. We have created a supportive and inspiring company culture that empowers individuals and …See details»
Clinical-stage Biotechnology Company | Endeavor …
Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead investigational candidate, ENV …See details»
Our Leadership Team - Endeavor BioMedicines
Prior to joining Endeavor BioMedicines, she was the Head of Human Resources at Evofem Biosciences, Inc., where she served as a part of the executive management team leading all …See details»
Endeavor BioMedicines - Crunchbase Company Profile …
Organization. Endeavor BioMedicines . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email info@endeavorbioMedicines.com; Phone Number 858.537.1700; …See details»
Endeavor BioMedicines - LinkedIn
Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases.See details»
Endeavor BioMedicines - PitchBook
Www.endeavorbiomedicines.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. 12707 High Bluff Drive; Suite 300; San Diego, CA …See details»
Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board …
SAN DIEGO, December 19, 2023--Endeavor BioMedicines, a clinical-stage company developing therapies for fibrotic disease and oncology, announced that the company has appointed …See details»
Endeavor BioMedicines Successfully Completes Phase 2a Trial of …
SAN DIEGO, January 24, 2024--Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients …See details»
Endeavor BioMedicines Partners with xCures to Identify Patients …
May 31, 2022 Please visit us on our website at www.endeavorbiomedicines.com and on our LinkedIn and Twitter pages. Contacts. Canale Comm Ingrid Mezo, Account Director …See details»
Endeavor BioMedicines Raises $132.5 Million Oversubscribed
Apr 24, 2024 SAN DIEGO--(BUSINESS WIRE)-- Endeavor BioMedicines, Inc. (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver …See details»
Endeavor Doses First Patient in Phase 2 Oncology Study …
May 25, 2022 Please visit us on our website at www.endeavorbiomedicines.com and on our LinkedIn and Twitter pages. Contacts. Canale Comm Ingrid Mezo, Account Director …See details»
Disruptive Science Targeting the Root Cause of Disease
Disruptive Science, New Therapeutic Possibilities. At Endeavor BioMedicines, we believe the greatest medical challenges demand more than incremental improvements; they require bold …See details»
Endeavor BioMedicines raises $62 million to combat pulmonary …
Jan 7, 2021 A new startup has officially emerged from stealth with the raise of its $62 million Series A funding round.Endeavor BioMedicines is led by co-founder and CEO John Hood, who …See details»
Endeavor raises $101m in Series B round to progress treatment …
Feb 8, 2022 ENV-201 is a small molecule ULK1/2 inhibitor to treat KRAS-driven cancers. The clinical-stage biotechnology company anticipates concluding investigational new drug (IND) …See details»
Endeavor BioMedicines Closes $101M Series B Financing to …
Feb 7, 2022 Please visit us on our website at www.endeavorbiomedicines.com and on our LinkedIn and Twitter pages. Contacts. Ingrid Mezo Canale Communications …See details»
Therapeutics Areas - Endeavor BioMedicines
We founded Endeavor BioMedicines to help patients with these intractable diseases. Focusing first on fibrotic lung diseases and cancer, we are committed to advancing therapies that will …See details»
Endeavor BioMedicines Closes $101M Series B Financing to …
Feb 7, 2022 Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the completion …See details»
Endeavor BioMedicines Launches with $62 Million Series A …
Jan 7, 2021 - Product candidate taladegib inhibits chronic Hedgehog signaling pathway, an underlying mechanism behind Idiopathic Pulmonary Fibrosis (IPF) - Two Phase 2 clinical …See details»
Endeavor BioMedicines Tackles Root Cause of Diseases
Sep 28, 2021 Endeavor BioMedicines, a clinical-stage precision medicine company, signed an exclusive licensing deal with the Salk Institute for Biological Studies and Sanford Burnham …See details»
Press Releases - Endeavor BioMedicines
Apr 24, 2024 Media Contact. Andrea Cohen Sam Brown Inc. 917-209-7163 AndreaCohen@sambrown.comSee details»